Wow, someone woke up on the wrong side of the bed. The references to PacBio and their latest claims are covered up in a paper-thin veil.
-
Wow, someone woke up on the wrong side of the bed. The references to PacBio and their latest claims are covered up in a paper-thin veil. -
"Cleaning up SHT™ with Illumina data"
lol -
It's a satire or a spoof of sequencing marketing & hype - timed with the AGBT meeting - not a specific dig at any one company! I thought it was brilliant.Comment
-
I didn't write it, as I said I was sent it by Neil Hall!Comment
-
Not sure I buy this. The all-consonant acronyms, the references to gold sponsors at AGBT (on the Twitter feed), the 99.999% consensus accuracy helped along by Illumina reads --- there are just too many coincidences. It is very funny but whoever wrote it definitely had PACB in mindOriginally posted by nickloman View Post
Comment
-
Maybe a little bitOriginally posted by BBoy View PostNot sure I buy this. The all-consonant acronyms, the references to gold sponsors at AGBT (on the Twitter feed), the 99.999% consensus accuracy helped along by Illumina reads --- there are just too many coincidences. It is very funny but whoever wrote it definitely had PACB in mind
Comment
-
It does rhyme with PacBio, but the salesmanship reminds me of another company instead
Comment
-
Frankly, the level of BS marketing involved in ALL sequencing machine provider is beyond me... When I see how much it actually costs society (purchase, red tape, infrastructure, qualification, service, usability and life span) to get one long read, I ask myself if the Talibans have won...Comment
-
-
Let's leave this thread alone here in the "PacBio" sub-forum - there's a thread over in "the pipeline" sub-forum on Oxford Nanopore,
http://seqanswers.com/forums/showthr...ewpost&t=17298Comment
-
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment